Liquid Biopsy Market Size, Share, Growth, Trends, and Forecast 2026–2034
According to Fortune Business Insights, the global liquid biopsy market size was valued at USD 11.66 billion in 2025. The market is projected to grow from USD 14.23 billion in 2026 to USD 106.49 billion by 2034, exhibiting a compound annual growth rate (CAGR) of 28.61% during the forecast period of 2026–2034. The market is experiencing significant growth due to the increasing prevalence of cancer, rising demand for early disease detection, and growing adoption of non-invasive diagnostic technologies. Additionally, advancements in molecular diagnostics, circulating tumor DNA (ctDNA) analysis, and next-generation sequencing (NGS) are supporting the adoption of liquid biopsy tests across healthcare settings.
Liquid Biopsy Market Overview
Liquid biopsy is a minimally invasive diagnostic procedure that involves analyzing biological fluids, particularly blood, to detect disease-related biomarkers. These tests identify circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), and other molecular components that provide valuable information about disease progression and treatment response.
Unlike conventional tissue biopsies, liquid biopsy procedures require relatively simple sample collection and can help healthcare professionals monitor cancer progression without repeatedly obtaining tumor tissue samples. These technologies are increasingly being used in cancer diagnosis, treatment selection, disease monitoring, and recurrence detection.
The growing focus on precision medicine and personalized healthcare is further increasing the demand for advanced liquid biopsy technologies. Pharmaceutical companies, diagnostic laboratories, and research institutions are investing in developing sensitive and reliable testing solutions to improve clinical outcomes.
Liquid Biopsy Market Trends
Increasing Adoption of Non-Invasive Cancer Diagnostic Technologies
One of the major trends supporting market growth is the increasing adoption of non-invasive diagnostic technologies for cancer detection and monitoring. Traditional tissue biopsies may involve invasive procedures, longer turnaround times, and difficulties in obtaining sufficient tumor samples.
Liquid biopsy offers an alternative by detecting cancer-related biomarkers through blood and other biological fluids. It can provide insights into tumor characteristics, genetic mutations, treatment response, and disease recurrence.
The growing adoption of these technologies among healthcare professionals is encouraging manufacturers to introduce advanced diagnostic solutions with improved sensitivity and accuracy.
Growing Demand for Precision Medicine and Personalized Treatment
The increasing focus on personalized medicine is creating significant opportunities for liquid biopsy technologies. These tests help healthcare professionals identify specific genetic alterations and select targeted therapies based on individual patient profiles.
Furthermore, liquid biopsy can support treatment monitoring by identifying molecular changes associated with drug resistance. This capability is particularly important for patients undergoing targeted cancer therapies.
The increasing use of molecular profiling and genomic testing is expected to strengthen the adoption of liquid biopsy solutions across oncology applications.
Advancements in Next-Generation Sequencing Technologies
Technological advancements in next-generation sequencing, digital PCR, and molecular diagnostics are transforming the liquid biopsy industry.
These technologies enable the detection of low-frequency genetic mutations and cancer-associated biomarkers in biological samples. Manufacturers are focusing on developing advanced assay kits and diagnostic instruments to improve testing efficiency and accuracy.
Additionally, ongoing research activities and collaborations between biotechnology companies and research institutions are supporting the development of innovative liquid biopsy platforms.
Request a Free Sample: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/liquid-biopsy-market-102506
Liquid Biopsy Market Growth Drivers
Rising Prevalence of Cancer Worldwide
The increasing prevalence of cancer is one of the primary factors driving the global liquid biopsy market. Growing cancer incidence is increasing the demand for early diagnosis, disease monitoring, and effective treatment selection.
Liquid biopsy tests can help identify cancer-associated biomarkers and monitor molecular changes during treatment. These capabilities are encouraging healthcare providers to adopt advanced diagnostic technologies.
Furthermore, the growing awareness of early cancer detection and increasing investments in oncology research are supporting market expansion.
Increasing Investments in Research and Development
Rising investments in research and development activities are contributing to the introduction of innovative liquid biopsy products. Leading companies are conducting clinical studies and developing advanced diagnostic assays to improve the detection of cancer-related biomarkers.
For instance, companies are increasingly investing in circulating tumor DNA analysis and genomic profiling technologies to expand the clinical applications of liquid biopsy.
Additionally, collaborations between diagnostic manufacturers, pharmaceutical companies, and research organizations are accelerating product development and commercialization.
Liquid Biopsy Market Restraints
High Costs Associated with Advanced Diagnostic Technologies
The high costs associated with liquid biopsy testing technologies may restrict their adoption, particularly in developing countries. Advanced diagnostic procedures involving next-generation sequencing and polymerase chain reaction technologies require specialized instruments, skilled professionals, and sophisticated laboratory infrastructure.
Furthermore, the expenses associated with clinical validation and product development can increase the overall cost of diagnostic solutions.
Limited reimbursement coverage and concerns regarding test accuracy in certain clinical applications may also restrict the widespread adoption of liquid biopsy technologies.
Liquid Biopsy Market Segmentation Analysis
The global market is segmented by product, application, and end user.
By Product
Based on product, the market is divided into kits and reagents and instruments.
The kits and reagents segment is expected to account for 80.08% of the global market in 2026. Its dominance is attributed to the increasing introduction of advanced diagnostic assay kits, growing demand for molecular testing, and rising adoption of genomic profiling technologies.
Manufacturers are focusing on developing innovative kits that offer improved sensitivity, faster processing, and reliable detection of cancer-associated biomarkers.
The instruments segment is also expected to experience growth due to increasing investments in advanced diagnostic equipment, digital PCR systems, and sequencing technologies.
By Application
Based on application, the market is categorized into oncology, non-invasive prenatal testing (NIPT), and others.
The non-invasive prenatal testing (NIPT) segment is anticipated to dominate the market, accounting for 68.69% of the global market in 2026. The segment's growth is supported by increasing awareness of prenatal screening, rising concerns regarding genetic abnormalities, and growing preference for non-invasive testing procedures among pregnant women.
Meanwhile, the oncology segment is expected to register comparatively higher growth during the forecast period. The increasing prevalence of cancer and rising demand for early diagnosis, treatment monitoring, and recurrence detection are supporting the adoption of liquid biopsy technologies in oncology.
By End User
Based on end user, the market is segmented into hospitals, clinical laboratories, and others.
The hospitals segment is expected to account for 75.01% of the global market in 2026. Its leading position is attributed to the increasing number of diagnostic procedures, growing adoption of prenatal screening, and rising availability of advanced diagnostic facilities in hospital settings.
Clinical laboratories are also expected to experience considerable growth due to increasing demand for specialized molecular diagnostic services and the expansion of laboratory testing infrastructure.
Liquid Biopsy Market Regional Outlook
North America
North America dominated the global liquid biopsy market with a 54.57% share in 2025, generating revenue of USD 6.36 billion. The regional market is projected to reach USD 7.75 billion in 2026.
The region's dominance is attributed to the presence of established biotechnology companies, increasing investments in cancer research, advanced healthcare infrastructure, and the growing adoption of precision medicine.
The U.S. market is projected to reach USD 7.33 billion in 2026, supported by rising demand for advanced cancer diagnostic technologies and increasing product development activities.
Europe
Europe accounted for 24.50% of the global market in 2025, with a valuation of USD 2.86 billion. The regional market is expected to reach USD 3.48 billion in 2026.
The growth is driven by increasing awareness of cancer screening, government initiatives supporting early disease detection, and rising investments in molecular diagnostics.
The U.K. market is expected to reach USD 0.46 billion in 2026, while Germany is projected to reach USD 1.01 billion during the same year.
Asia Pacific
Asia Pacific accounted for 18.22% of the global market in 2025, generating USD 2.13 billion in revenue. The regional market is projected to reach USD 2.62 billion in 2026 and is anticipated to register the highest CAGR during the forecast period.
The growth is supported by increasing healthcare expenditure, rising awareness of genetic screening, expanding diagnostic infrastructure, and growing demand for non-invasive prenatal testing.
Japan is projected to reach USD 0.72 billion in 2026, China is expected to reach USD 0.55 billion, and India is anticipated to reach USD 0.39 billion.
Latin America
The Latin America market accounted for approximately USD 0.22 billion in 2025, representing 1.90% of the global market. It is projected to reach USD 0.27 billion in 2026.
Increasing cancer prevalence, growing demand for diagnostic testing, and the expansion of hospital and laboratory infrastructure are supporting regional market growth.
Middle East & Africa
The Middle East & Africa market accounted for 0.80% of the global market in 2025, reaching USD 0.09 billion. The regional market is expected to grow to USD 0.11 billion in 2026.
Increasing awareness of prenatal screening, improving healthcare infrastructure, and rising demand for advanced diagnostic procedures are expected to support market expansion.
Competitive Landscape of the Liquid Biopsy Market
The global liquid biopsy market is characterized by the presence of established biotechnology companies, diagnostic manufacturers, and molecular testing providers. Key players are focusing on product innovation, strategic collaborations, clinical research, and regulatory approvals to strengthen their market positions.
Companies are also investing in advanced genomic profiling technologies and developing diagnostic solutions for cancer detection, treatment selection, and disease monitoring.
Major companies operating in the global liquid biopsy market include:
- Guardant Health, Inc.
- Personalis, Inc.
- Foundation Medicine, Inc.
- Natera, Inc.
- Illumina, Inc.
- Hoffmann-La Roche Ltd.
- Menarini Silicon Biosystems, Inc.
- Thermo Fisher Scientific Inc.
- QIAGEN
- Bio-Rad Laboratories, Inc.
Read Report Insights: https://www.fortunebusinessinsights.com/liquid-biopsy-market-102506
Future Opportunities in the Liquid Biopsy Market
The global liquid biopsy market is expected to witness significant opportunities through advancements in molecular diagnostics and increasing demand for personalized healthcare.
The growing application of liquid biopsy in early cancer detection, minimal residual disease monitoring, and treatment response assessment is creating new opportunities for manufacturers.
Additionally, the increasing use of artificial intelligence and advanced genomic analysis tools may improve the interpretation of molecular testing results. Emerging markets are also expected to provide growth opportunities as healthcare infrastructure improves and awareness of advanced diagnostic procedures increases.
The expansion of clinical research, increasing investments in biotechnology, and development of cost-effective diagnostic solutions are expected to support the industry's long-term growth.
Frequently Asked Questions (FAQs)
- How big is the global Liquid Biopsy Market?
According to Fortune Business Insights, the global liquid biopsy market size was valued at USD 11.66 billion in 2025. The market is projected to grow from USD 14.23 billion in 2026 to USD 106.49 billion by 2034.
- What is the projected CAGR of the Liquid Biopsy Market?
The global liquid biopsy market is expected to register a CAGR of 28.61% during the forecast period of 2026–2034, driven by increasing cancer prevalence and growing demand for non-invasive diagnostic technologies.
- Which segment dominates the Liquid Biopsy Market?
By product, the kits and reagents segment is expected to dominate, accounting for 80.08% of the market in 2026. By application, non-invasive prenatal testing is anticipated to hold the leading share of 68.69%.
- What are the major factors driving the Liquid Biopsy Market?
The major growth drivers include rising cancer prevalence, increasing demand for early disease detection, advancements in next-generation sequencing, growing adoption of precision medicine, and increasing investments in molecular diagnostic research.
- Who are the key players in the Liquid Biopsy Market?
Major companies operating in the global market include Guardant Health, Inc., Personalis, Inc., Foundation Medicine, Inc., Natera, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd., Menarini Silicon Biosystems, Thermo Fisher Scientific, QIAGEN, and Bio-Rad Laboratories.
What’s Driving Japan’s Market? Discover the Latest - Liquid Biopsy Market- Insights